Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer
NCT04516616Phase 2Active, not recruiting
- Sponsor
- Huazhong University of Science and Technology
- Start
- Dec 2020
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Cervical Cancer (CC), sponsored by Huazhong University of Science and Technology. Started Dec 2020; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04516616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04516616.